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Abstract  
AIM: This study aimed to investigate the value of DNA ploidy and galectins-3 immunostain in the 
preoperative evaluation of thyroid epithelial lesions. 
MATERIAL AND METHODS: Sixty patients presenting with thyroid enlargement were included in 
this study and referred by clinicians for FNA. Routine cytological evaluation was done on PAP   
stained slides according to the WHO criteria and at least three slides were prepared for routine 
cytological examinations. The nuclear DNA analysis was performed at the Pathology Department, 
National Research Center using the Leica Qwin 500 Image Analyzer (LEICA Imaging Systems Ltd, 
Cambridge, England). Galectin-3 expression was investigated in all tissues using streptavidin-biotin 
technique. 
RESULTS: Conventional Fine needle aspiration cytology (FNAC) of 60 cases could diagnose 
malignancy with a sensitivity of 60%, negative predictive value (NPV) 71.4%, and overall diagnostic 
accuracy of 80%. The aneuploidy was significantly associated with malignancy, with sensitivity 
90.9%, specificity 83.3% and accuracy 88.3%. On using galectin-3 immunocytochemichal stain on 
cell blocks prepared from FNA the values were improved, sensitivity 93.3% specificity 86.7% and 
overall accuracy 90% and it was noticed that galectin-3 over expression was significantly 
associated with malignancy. 
CONCLUSIONS: From the results of this study we can consider that DNA ploidy and Galectin-3 
could refine the FNA results and  increase its sensitivity as a screening test from sensitivity(60%) to 
reach sensitivity (93.3%), thus decreasing the false negative cases. From this study, it is concluded 
that the application of ancillary techniques as galectin-3 immunocytochemical markers may become 
a reliable indicator for surgical intervention, DNA ploidy measurements on the other hand may be of 
value in galectin-3 negative cases to determine the behavior of the lesion in such cases & refine the 
preoperative assessment by out ruling false negative cases. 
 
 
 
Introduction 
 
Thyroid gland disease is one of the most 
common endocrine diseases. The incidence may vary 
considerably; and in endemic goiter areas, the thyroid 
nodules may be as high as 25% or more. In non- 
iodine –deficient areas, 4% to 7% of the population 
has thyroid [1]. Prophylactic operations for all thyroid 
nodules seems unreasonable and is not cost-
effective, as four of five nodules are benign. 
Refraining from surgery can be done safely only when 
the risk to postpone removal of malignant disease is 
low [2]. Thus the need for reliable preoperative 
diagnosis is great. 
Fine needle aspiration cytology (FNAC) has 
emerged as a valuable, popular and routine 
investigation that can differentiate between benign 
and malignant thyroid nodules, with no or minimal 
complications [3]. However, the diagnostic efficacy of 
FNA declines sharply in the diagnosis of follicular 
patterned lesions of thyroid and up to 30% of patients 
with nodular thyroid disease will receive a FNA report 
that reads “follicular lesions” or “suspicious”. Most of 
these patients will require surgical management, and 
the extent of resection will need to be planned without 
a preoperative diagnosis of malignancy [4].  
It has been shown that the malignancy rate in 
cases diagnosed as follicular lesions can be up to 
20%. This high rate of benign lesions undergoing 
surgery is because FNA cannot differentiate between 
follicular adenoma and well-differentiated carcinoma 
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based on cyto-morphology. This distinction is made 
only by demonstration of capsular and vascular 
invasion upon histopathologic examination [5].  
All this leads to low frequency of thyroid 
carcinoma recognition at early stages and 
necessitates the development and adoption of new, 
more sensitive methods for oncologic diagnosis. To 
date, no effective method has been established to 
identify malignant follicular tumors of the thyroid 
preoperatively. 
Many studies suggested that DNA ploidy 
studies may be a helpful scientific tool in identification 
of neoplastic epithelial follicular cells, as DNA euploidy 
excludes the presence of neither malignancy nor 
neoplasia [6, 7].  Furthermore, many studies have 
also demonstrated that nuclear DNA content and 
ploidy assessment may be a prognostic factor for 
patients of thyroid carcinomas [8]. 
Recent advances in molecular diagnostics, 
such as immunocytochemistry and enzyme activity 
assays, allowed a further analysis of FNA material in 
an attempt to differentiate benign from malignant 
thyroid nodules [9]. Several molecules involved in 
carcinogenic processes have been proposed as 
markers of thyroid malignancy [10, 11]. 
Galectin-3 (GAL-3) seems to be one of the 
most promising molecules in increasing thyroid FNAC 
accuracy [12, 13]. As reported in several studies this 
lectin is expressed in thyroid carcinoma but not in 
normal thyrocytes and in benign lesions such as 
follicular adenomas [14]. In particular, many studies 
reported that cytoplasmic GAL-3, selectively 
expressed in malignant thyroid cells, is easily 
detectable also on FNA cytologic samples [12, 15].
 
 
The aim of this work is to evaluate the 
complementary diagnostic role of DNA image analysis 
and immunocytochemistry study using Gal-3 as 
diagnostic adjuvant to thyroid fine needle aspiration 
cytology, aiming to improve the preoperative 
assessment of the potential biological behavior of 
follicular lesions.  
 
 
Material and Methods 
 
Sixty patients presenting with thyroid 
enlargement were included in this study and referred 
by clinicians for FNA (to Cytology unit of Kasr Al-Aini 
Hospital- Pathology Department, and the Cytology 
unit in National Cancer Institute as well as several 
private labs). Consents were obtained from all cases 
according to the formula documented from the ethical 
committee in the National Research Center. Ethical 
approvals were obtained from the Medical Ethical 
Committee of National Research Center (NRC), and 
Kasr Al-Aini Research Ethical Committee (REC).  
Routine cytological evaluation was done on 
PAP   stained slides according to the WHO criteria 
[16] and at least three slides were prepared for routine 
cytological examinations. 
For cell blocks preparation, the correct 
amounts of 10% buffered formalin was used for 
fixating the remainder of the aspirated material and 
then centrifuged. The formed pellet was then paraffin 
embedded [14]. One formalin fixed paraffin-embedded 
section was prepared for H&E staining and reviewed 
for adequacy for further Fuelgan and immunostaining  
which are performed on adequate samples. 
Another two paraffin sections were cut at 4 
micron thicknesses. One section was placed on 
electrocharged “plus” slides, which allows strong 
adhesion for tissues and minimizes tissue detachment 
during antigen retrieval in immunocytochemical 
procedures. The second was placed on ordinary slide 
for Felugan staining and DNA study. 
 
DNA content analysis 
The Feulgen staining reaction specifically 
stains the DNA to give specific staining of the nuclear 
DNA. Nucleoli and cytoplasm should show no 
staining. The nuclear DNA analysis was performed at 
the Pathology Department, National Research Center 
using the Leica Qwin 500 Image Analyzer (LEICA 
Imaging Systems Ltd, Cambridge, England,)   
Distorted or overlapping nuclei and nuclear 
fragments were manually eliminated from 
measurement. All these facilities were supplied as 
editing function in the Leica Qwin 500 image analysis 
systems. 
The optical density of the selected nuclei in 
each microscopic field is then measured and 
automatically converted by the system into DNA 
content. Many fields were selected until the desired 
number of nuclei (100 – 150) had been measured. 
The results were displayed as a frequency 
histogram on the monitor generated by plotting the 
DNA content versus the number of nuclei counted. 
Then scaling of the data was automatically performed 
by the system for optimal resolution, interpretation, 
and statistical assessment. All nuclear populations 
present in a tumor were represented in the histogram. 
The DNA histograms were classified 
according to Danque et al. [17] as diploid, tetraploid 
and aneuploid based on the amount of DNA relative to 
the normal control. The diploid position (2c) for the 
study population was determined after calibration of 
the system.  
DNA histograms obtained by image analysis 
are classified as follows:  
Diploid type, when a single peak is found in 
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the diploid or near diploid region, and fewer than 20% 
of the cells are present at the tetraploid position.  
Tetraploid type, when there is a peak in the 
diploid region and a second peak with more than 20% 
of the cells in the tetraploid region. Aneuploid type, 
when at least 10% of the total events show a distinct 
abnormal peak outside the 2C or 4C position.  
Both the diploid and the tetraploid patterns 
were grouped together as (non –aneuploidy), so 
results displayed as aneuploid and non aneuploid [8, 
18]. 
 
Immunocytochemical methods 
Galectin-3 expression was investigated in all 
tissues using streptavidin-biotin technique. Four-um 
thick sections were deparaffinized, hydrated and 
incubated in 3% hydrogen peroxide for 30 minutes to 
block the internal peroxidase activity. Antigen retrieval 
was done by microwave pretreatment for 10 minutes 
in 0.01M citrate buffer. The slides were incubated at 
4°C overnight with mouse monoclonal anti- Galectin-3  
antibody (THERMO SCIENTIFIC. Cat. No. MS- 1756-
S0(0.1)).These steps were followed by a 30- minutes 
incubation with biotinylated horse anti-mouse antibody 
at room temperature, then avidin-biotin peroxidase 
complex for 60 minutes at room temperature and 
finally diamiobenzidine (DAB) for 3-5 minutes. The 
slides were counterstained with hematoxylin, 
dehydrated and mounted.  
 
Positive control 
Sections from small intestine were prepared 
and stained. Positive cytoplasmic staining was 
demonstrated in the epithelial cells [14]. 
 
Negative control 
Sections of the same tissues which were used 
as positive control are processed in the same 
immunostaining procedure but the negative control 
serum was used instead of the primary antibody. 
 
Scoring of the immunocytochemistry 
Immunostaining were evaluated blindly 
without knowledge of the previously established 
histological diagnosis. Galectin -3 stained slides 
immunostains were considered positive if definitive 
cytoplasmic staining -with or without nuclear staining- 
was detected (the macrophages and stromal cells 
used as a positive internal control being positive).  
Galectin-3 immunostaining was graded using 
the following semi-quantitative scale: (-) no reactivity, 
+/- focal reactivity (<10% of the neoplastic cells), + 
moderate reactivity (10-50% of the neoplastic cells) 
and ++ diffuse positivity (>50% of the neoplastic cells) 
[14].  
Statistical analysis 
Data were statistically described in terms of 
range, mean, standard deviation ( SD), median, 
frequencies (number of cases) and relative 
frequencies (percentages) when appropriate. 
Comparison of the study variables between 
benign and malignant cases in the present study was 
done using Mann Whitney U test for independent 
samples. Comparison of the study variables between 
all pathological types in the present study was done 
using Kruskal Wallis analysis of variance (ANOVA) 
test with posthoc multiple 2-group comparisons. 
Accuracy was represented using the terms 
sensitivity, specificity, positive predictive value, 
negative predictive value, and overall accuracy.. 
A probability value (p value) less than 0.05 
was considered statistically significant. All statistical 
calculations were done using computer programs 
Microsoft Excel version 7 (Microsoft Corporation, NY, 
and USA) and SPSS (Statistical Package for the 
Social Science; SPSS Inc., Chicago, IL, USA) 
statistical program.  
 
 
Results 
 
The present study included 60 FNA biopsies 
of different epithelial follicular lesions, divided 
according to the final histopathological diagnosis (post 
thyroidectomy) into: 16 cases of nodular goitre, 14 
cases of follicular adenoma, 18 cases of papillary 
carcinoma, and 12 cases of follicular carcinoma.  
Clinically, thyroid enlargement was the main 
presenting symptom for the patients.  In all patients of 
multinodular goitre, the thyroid enlargement was 
asymmetrical with a lobulated nodular surface on 
palpation. The same clinical findings were also seen 
in 3 patients of follicular adenoma, while rest of the 
adenoma cases [11] presented as solitary thyroid 
nodules. 
Three patients with papillary carcinoma had 
asymmetrical enlargement with nodular surface, and 
the rest [15] presented as single nodules. All included 
cases of follicular carcinoma presented clinically as 
solitary thyroid nodules. Single nodularity was 
significantly associated with neoplasia (P = 0.00231), 
and with malignancy (P = 0.00341). 
By FNAC 17 cases were benign, 25 were 
diagnosed as Follicular neoplasm, two were 
suspicious of malignancy (intermediate) and 16 were 
malignant (Table 1). 
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Table 1: Cytologic diagnosis of the cases. 
Diagnostic category No. of cases % 
Benign 
Follicular neoplasm 
Suspicious 
Malignant 
Total 
17 
25 
2 
16 
60 
28.3% 
41.7% 
3.3% 
26.7% 
100 % 
     
Conventional FNAC was found to predict 
benignity in 87.5% of MNG cases, but only in 21.4% 
of adenoma cases. Rest of adenoma cases and all 
the FTC cases were placed in the indeterminate group 
of “follicular neoplasm”.  
Table 2: Results of FNA compared to histopathological 
diagnoses. 
Cytology 
 
Pathology 
 
Benign 
 
Follicular 
Neoplasm 
 
Suspicious 
for malignancy 
 
Malignant 
 
Total 
MNG 14 2 0 0 16 
FA 3 11 0 0 14 
Benign     
groups 
17 13 0 0 30 
PTC 0 0 2 16 18 
FTC 0 12 0 0 12 
Malignant 
groups 
0 12 2 16 30 
 
Total 
17 25 2 16 60 
 
Of the indeterminate cytology group “follicular 
neoplasm” 48% proved histologically to be follicular 
carcinomas. 
As expected, FNAC diagnosed (or at least 
suspected) malignancy in all cases of papillary 
carcinomas, with no false positive cases (specificity 
100%) (Table 2).         
Conventional FNAC could diagnose 
malignancy with sensitivity of  60%, negative 
predictive value(NPV) 71.4%, specificity and positive 
predictive value(PPV) 100%(no false positive 
cases),and overall diagnostic accuracy of 80%.  
   
DNA ploidy in studied groups 
The Leica Qwin 500 image analyzer 
automatically expresses the DNA content of each 
individual cell selected and gives the percentage of 
each cell class out of the total number of cells 
examined (100-110 cells per case). DNA content of 
2C is diploid while, DNA content of 4.5C or more 
indicates aneuploidy.  
Table 3: DNA distribution in different studied groups. 
Studied groups No DNA ploidy distribution 
Diploid 
No. ( %) 
Aneuploid 
No. ( %) 
MNG 16 9 (56.3)* 2 (12.5) 
FA 14 10 (71.4) 4 (28.6) 
FTC 12 2 (16.7) 10 (84.3) 
PTC 18 2 (11.1) 16 (88.9) 
Total 60 23 (38.3) 32 (35.3) 
*: 5 cases MNG were hypoploid. 
 
Of the total malignant cases; aneuploidy was 
found in 86.7%of cases with 13.3% of malignant 
cases showed diploid pattern. 
DNA aneuploidy was significantly associated 
with malignancy (p = 0.00074), with sensitivity 90.9% 
and specificity 83.33% and overall diagnostic 
accuracy 88.29% in identifying malignancy from 
thyroid aspirate. 
Within the benign cases; two cases out of 16 
cases of nodular goitre showed aneuploidy (12.5%), 9 
cases (56.3 %) were diploid and the remaining 5 
cases were hypoploid.  Four adenoma cases were 
aneuploidy (28.6%), while rest of follicular adenoma 
cases were diploid (71.4%)  
Significant differences were observed 
between follicular adenoma and follicular carcinoma 
(p = 0.000337), and between papillary carcinoma and 
MNG (P = 0.0024). 
 
 
 
 
Figure 1: Histogram comparing DNA content in 1-A: follicular 
adenoma versus the control, cells had one peak at 2C region 
(diploid); 1-B: follicular carcinoma case versus the control, most of 
cells contained DNA content above 2C (aneuploidy); 1-C: in 
papillary carcinoma versus the control; most of cells contained DNA 
content >4.5, with peak outside the diploid and tetraploid areas 
(aneuploid). 
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Galectin-3 immunohistochemical expression 
Immunocytological analysis of Galectin-3 in 
cases of MNG, showed absent cytoplasmic 
expression in 15 cases out of the included 16 cases, 
and only one case showed moderate reactivity (10-
50% of cells). 
Cases of follicular adenoma showed absent 
cytoplasmic expression in 11 cases, two cases 
showed focal positivity (< 10%), and one case was 
moderately positive (10-50%).  The three of the 
aforementioned positive cases were histologically 
cellular microfollicular adenomas. 
All the cases of papillary carcinoma showed 
diffuse reactivity to the Galectin-3 (> 50% of 
neoplastic cells), while 8 cases of follicular carcinoma 
were diffusely positive, two cases were moderately 
positive, and two cases were completely negative. 
The nuclear staining in the absence of the 
cytoplasmic staining was considered non specific and 
negative. Inflammatory cells, endothelial cells and 
stromal cells expressed Galectin-3 in all cases 
(internal positive control). 
 
Table 4: Galectin-3 scoring in the studied groups. 
Studied 
groups 
No. 
Galectin-3 scoring 
- -/+ + ++ 
Absent 
0% 
Focal 
<10% 
Moderate 
10-50% 
Diffuse 
>50% 
No. ( %) No. ( %) No. (%) No (%) 
MNG 
FA 
PTC 
FC 
Total 
16 
14 
18 
12 
60 
15 (93.8) 
11 (71.4) 
0  (0) 
2 (16.6) 
28 (43.3) 
0  (0) 
2 (14.3) 
0 (0) 
0 (0) 
2 (5) 
1 (6.2) 
1 (14.3) 
0 (0) 
2 (16.6) 
4 (8.3) 
0  (0) 
0  (0) 
18 (100) 
8 (66.7) 
26 (33.3) 
 
The total galectins-3 positivity percentage was 
93.3% in malignant cases in comparison to non-
malignant cases (13.3%) and the difference was 
highly statistically significant (p = <0.0023).  
PTC cases showed optimum positivity 
percentage (100%), compared with (83.3%) positivity 
percentage in FTC cases. 
According to these results, galectins-3 could predict 
malignant outcome in 28 out of 30 cases of the 
malignant cases included in the study, with sensitivity 
93.3%, specificity 86.7%, positive predictive value 
87.5%, and negative predictive value 92.9%. The 
overall accuracy was 90%. 
Table 5: Expression of Galectin-3 in the studied groups. 
 
Studied groups 
 
 
No. 
Galectin-3 expression 
Negative                     Positive 
No. (%)                     No. (% ) 
Benign Lesions 
MNG 
FA 
Total 
 
Malignant Lesions 
PTC 
FC 
Total 
 
Total 
 
16 
14 
30 
 
 
18 
12 
30 
 
60 
 
15 (93.8)                     1 (6.2) 
11 (71.4)                     3 (28.6) 
26 (86.7)                     4 (13.3) 
 
 
0 ( 0)                        18 (100) 
2 (16.6)                    10 (83.3) 
2 (16.6)                    28 (93.3) 
 
28 (48.3)                  32 (51.7) 
        
Overall, Galectins-3 over-expression 
(moderate or diffuse positivity) was remarkably 
associated with malignant results; as it was found in 
28/30 malignant cases, while only 2/30 benign cases 
(one MNG and one follicular adenoma), showed 
moderate Galectin-3 positivity, and the difference was 
statistically significant (p = 0.0021).  
  
The results of Gal-3 and DNA ploidy in cases 
of “follicular neoplasm” group 
This group constituted 25 of the studied cases 
(41.7%). The conventional FNA can not go further 
than this diagnostic terminology, Referring to the gold 
standard histopathologic diagnoses, it was noted that:  
1. Immunocytochemical staining by Gal-3 could 
screen malignancy within this indeterminate 
group with sensitivity 83.3%, specificity 
84.6%, and 84% diagnostic accuracy. 
2. DNA ploidy could diagnose malignancy within 
this group with sensitivity 83.3%, specificity 
76.9%, and 80% diagnostic accuracy. 
 
The results of the different studied techniques 
versus the results of the conventional FNA 
Overall, the ancillary techniques used in the 
study (Galectin-3 and DNA ploidy) could refine the 
FNA results and increase its sensitivity as a screening 
test from sensitivity (60%) to reach sensitivity (93.3%), 
thus decreasing the false negative cases (Figure 2). 
The assessment of the proliferative activity by PI can 
suggest the lesion behaviour and support the FNA 
and other studies results (Table 6). 
Table 6: Compared efficacy of different studied techniques. 
Studied Technique Sensitivity Specificity 
Diagnostic 
accuracy 
FNAC 60% 100% 80% 
Gal-3 93.3% 86.7% 90% 
DNA Ploidy 90% 83.3% 88.3% 
 
 
 
Discussion 
 
During the last years, confidence in fine 
needle aspiration cytology (FNAC) has grown 
considerably and cytology has been widely accepted 
as an initial step in thyroid nodules management.  By 
the routine use of FNAC in thyroid nodules 
assessment, fewer patients were subjected to surgical 
treatment for benign diseases and the rate of thyroid 
surgery was cut in half, which resulted in substantial 
savings in health care expenditures [19]. 
However, although the fact that FNA is the 
most accurate, cost- effective and specific test 
adopted for pre-surgical evaluation of thyroid nodules,  
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Figure 2: Cell block stained with galectins-3 of: 2-a: Follicular 
adenoma showing negatively stained follicular cells, some stromal 
cells stained positive as internal positive control                          
(galectin-3 x 400). 2-b: Follicular carcinoma showing diffuse 
cytoplasmic positivity (> 50% of cells) (galectin-3 x 200). 2-c: 
papillary carcinoma with focal strong cytoplasmic staining,                           
(galectin-3 x 200). 
 
up to 30% of patients with nodular thyroid disease will 
receive a FNA report that reads “follicular lesions” or 
“follicular neoplasm” [20]. This indeterminate category 
is the major limitation of the technique and the most 
problematic in terms of risk assessment and patient 
counseling, with the malignancy found in about 10-
20% of these nodules. Due to this high incidence of 
malignancy, most patients with thyroid nodules of 
indeterminate cytology are referred for surgical 
resection [21] usually in the form of diagnostic 
hemithyroidectomy. Moreover, those with proved 
carcinoma will then require a second- stage 
completion thyroidectomy with or without neck 
dissection and post operative iodine [22]. In contrast, 
when the cytological report could clearly exclude 
malignancy, most surgeons choose to observe, unless 
associated with compression symptoms [23]. 
Thus, to overcome this well known limitation 
and to improve the diagnostic yield of FNAC, many 
modern techniques have been introduced and applied 
to thyroid cytology smears. These techniques include; 
morphometric studies, immunocytochemical studies, 
DNA ploidy analysis, PCR, cytogenetics, and even 
electron microscopic examinations [24, 25]. 
The aim of the current study is to evaluate 
whether DNA ploidy and Galactin-3 expression could 
help in solving the diagnostic dilemma of 
indeterminate cytology, either alone or in combination, 
thereby improving the selection criteria for cases 
referred for surgery and aiming at avoiding 
unnecessary surgical interventions. 
In the present study 60 Samples were 
obtained prospectively from patients presenting with 
thyroid enlargement and referred by clinicians for FNA 
to the Cytology unit of Kasr Al-Aini Hospital- 
Pathology Department and   the Cytology unit at the 
National Cancer Institute (NCI) as well as several 
private labs.  
The 60 cases of thyroid epithelial lesions were 
categorized according to the post surgical 
histopathologic diagnoses as:  nodular goiter (16 
cases), follicular adenoma (14 cases), papillary 
carcinoma (18 cases), and follicular carcinoma (12 
cases), with 50% of cases were benign and 50% were 
malignant. 
A solitary thyroid nodule was the main 
presenting symptom in 78.6% of adenoma cases, 
83.3% of papillary carcinoma cases and in all cases of 
follicular carcinoma. Thus, the presence of a single 
nodule clinically (or sonographically) was significantly 
associated with neoplasia and malignancy. The same 
findings were also mentioned by Raba et al. [26] and 
Giles et al. [27]. Rago et al. [28]
 
and Lubiz et al. [29]  
also  recorded  the same finding  and recommended” 
single nodularity” as a risk factor for thyroid 
malignancy.  
Although Pedamallu & Pedamallu [30], and 
Tuille et al. [31] made the same observation,  they 
also pointed to the percentage of malignant cases in 
clinically nodular enlargement, and recommended that 
the risk of thyroid neoplasia and malignancy in this 
setting not to be underestimated, and that nodular 
thyroid enlargement should be subjected to FNA to 
exclude neoplasia and malignancy especially in the 
presence of risk factors, family history, dominant 
nodules or sonographically suspicious nodules. 
According to the present study results, the 
conventional cytological examination could perfectly 
diagnose (or suspect) cases of papillary carcinoma 
with no false positive results. Esmaili and Taghipour 
[32] got similar results with no false positive cases 
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(specificity 100%). Like wise, Siddiqiui et al. [33] 
stated that missed diagnosis of PTC on FNA may 
occur only because of inadequate tumor sampling due 
to the heterogeneity of the nodule targeted for FNA. 
Flanagan et al. [34], also reported similar results and 
concluded that false positive reports do not constitute 
a major problem in thyroid FNAC for papillary cancer.  
However this was not the case in other 
groups where conventional FNAC could predict 
benignity in 87.5% of MNG cases, and only in 21.4% 
of adenoma cases. The rest of the adenoma and 
MNG cases as well as all the FTC cases were placed 
in the indeterminate group of “follicular neoplasm”, 
48% of these cases proved histologically to be 
follicular carcinoma.  
Ogilvie et al. [4], Rosaria et al. [35] and 
Faquin [36] agreed that the cytological diagnosis of 
follicular neoplasms are indeterminate and form a 
grey zone in thyroid FNA cytology, requiring  further 
characterization by demonstration of  capsular and/or 
vascular invasion upon histological examination.   
According to our results and analysis, the 
overall diagnostic accuracy of conventional FNA was 
80%. Thapa et al. [3] and Yang et al. [37] recoded an 
accuracy rate above 90% for conventional FNA.   
Although Haugan et al. [38], Cochand-priollet 
et al. [39] and Hayashi & Kitaoka [40] have 
documented the excellent overall diagnostic accuracy 
of thyroid FNA; they suggested the use of additional 
ancillary techniques as a way to improve the 
indeterminate or suspicious results that pose 
diagnostic and management dilemma. 
           In the present study, DNA ploidy measurement 
by image analysis, and immunocytochemical staining 
for Galectin-3 were evaluated for their role in 
improving the diagnostic accuracy of thyroid FNAC. 
The first ancillary test evaluated in the study 
was DNA ploidy assessment by image analysis 
system. Study of cases was done using Leica 
Qwin500 image analyzer. DNA content of 4.5 or more 
indicates aneuploidy, the case is considered 
aneuploid when at least 10% of the total events show 
distinct abnormal peak outside the 2c (diploid) or 4c 
(tetraploid) positions. Both the diploid and the 
tetraploid patterns were grouped together as (non –
aneuploidy), so results displayed as aneuploid and 
non aneuploid [18, 19]. 
In the current study, aneuploidy was 
significantly associated with malignancy; highest 
mean value was noticed in papillary carcinoma. In 
papillary carcinoma 88.9% of cases in this study 
showed aneuploidy and only two cases (11.1%) were 
non-aneuploid. In follicular carcinoma 83.3% of cases 
were aneuploid and also two cases (16.7%) were non-
aneuploid. In the benign cases, aneuploidy was seen 
in 2 cases of nodular goiter and in 4 cases of follicular 
adenoma. 31.3% of nodular goiter cases were 
hypoploid (most of cells less than 2C), rest of both 
groups cases were diploid. Aneuploidy was seen   in 
86.7% of malignant cases but only in 20% of benign 
cases with sensitivity 90.9%, specificity 83.3% and 
accuracy 88.3% in identifying malignancy in thyroid 
aspirate. 
Similar results were recorded by Frasoldati  et 
al. [41] and Bakr et al. [42] and they concluded that 
aneuploidy was significantly more frequent in 
malignant cases. However, they also observed that 
aneuploidy was not exclusive of malignancy; 
aneuploid follicular adenomas exist and they may 
represent cases undergoing malignant transformation. 
Nadjari et al. [43] got a higher sensitivity in using 
image analysis (100%), and none of the benign cases 
included in that study showed aneuploidy. Sturgis et 
al. [19] studied aneuploidy in papillary carcinoma 
cases and they proved a strong association between 
aggressive DNA pattern (aneuploidy) and both distant 
metastasis and death from the disease, and linked the 
non aggressive (non-aneuploid) results in papillary 
carcinoma with a better prognosis. Orell et al. [44] 
also suggested that aneuploid papillary carcinoma 
have a higher rate of recurrence, morbidity and 
mortality that non-aneuploid ones. 
Francis et al. [45] explained the aneuploid 
nodular goitre cases by the possible development of 
chromosomal aberrations and/or the selection of 
cellular clones with high growth potential. Konarska et 
al. [46] recorded the presence of nodular goitre cases 
with hypoploid DNA pattern; however they did not 
suggest an explanation.  In our study, we suppose 
that these hypoploid cases may represent 
degenerative changes and cystifications, which are 
common in nodular goitre.   
Onaran et al. [18], Camargo et al. [47] and 
Missaoui et al. [48] claimed a strict correlation 
between aneuploid DNA content in thyroid cells and 
tumor stage and behavior and they concluded that 
DNA measurement in FNA may be a useful adjunct 
method in thyroid lesion analysis, and may influence 
the extent of surgery as well as prognosis evaluation. 
On the other hand, some authors were less optimistic. 
Konarska et al. [46] and Lewinski [49] suggested that 
aneuploidy was a common feature in histopathological 
benign thyroid lesions, and they concluded that 
aneuploid was not found specific to any type of thyroid 
lesions and therefore could not be of clinical value in 
diagnosing malignancy from FNA. In 2005, Cusick et 
al. [50] noticed that DNA aneuploid benign and 
malignant thyroid lesions appeared to give parallel 
results, so they suggested cell cycle analysis to help 
in distinguishing benign from malignant thyroid 
lesions.     
The present study results were in 
concordance with Frasoldati et al. [41] and Konarska 
et al. [46] who provided significantly higher mean PI in 
carcinomas than in benign lesions, and stated that PI 
values were independent of DNA ploidy level. 
Galectin-3 is a component of soluble beta-galactoside 
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binding lectins, which is up-regulated in thyroid 
carcinoma, while its expression in normal and benign 
thyroid tissue is absent or weak. In many studies, 
galectin-3 had been reported to be very sensitive and 
reliable marker for the preoperative identification of 
thyroid carcinoma with high sensitivity and specificity 
in cytological cell blocks and routine cytological 
samples [15]. 
According to our results, Galectins -3 over-
expression was significantly associated with 
malignancy as it was strongly expressed (moderate or 
diffuse positivity) in 28/30 malignant cases, compared 
to 2/30 benign cases. Pennelli et al. [51] and Chiu et 
al. [52] agreed that Galectin-3 over-expression 
(moderate and diffuse scoring) was a good predictor 
for thyroid cancer and an unequivocal indication for 
surgery. Nearly similar values of sensitivity, specificity 
and accuracy were also reached by Saggiorato et al. 
[14], Bartolazzi et al. [15]
 
and Aiad et al. [53], all  
suggested that the routine correct  use of galectin-
3can increase the diagnostic accuracy of conventional 
cytology especially in the indeterminate group,  hence 
improve the management of thyroid nodules and 
reduce unnecessary  thyroid surgeries.   
              On the other hand, Aron et al. [12] and Kim et 
al. [13] disagreed with these results and both pointed 
to the poor specificity of galectins-3   because of its 
reactivity in some benign cases (false positive cases). 
Mehrotra et al. [22] and Oestreicher-Kedem et al. [54] 
also have found that galectin-3 is not a sensitive 
indicator of thyroid cancer because of the possibility of 
false negative cases. 
In this  study, all papillary carcinoma cases 
showed diffuse expression of Galectin-3, the finding 
which was also highlighted by Haugen et al. [38] and 
Pennelli et al. [51],  and was explained by Yoshii et al. 
[55] as the expression of Galectin-3 appears to be 
necessary for the maintenance of transformed thyroid 
papillary cancer cell line in vitro. Papotti et al. [56] 
agreed also with this finding and put great emphasis 
on the role of Galectin-3 in differentiating between 
cystic papillary carcinoma and benign thyroid cysts. 
In the present study, 83.4% of follicular 
carcinoma cases were positive for Galectin-3, while 
16.6% showed a negative reaction. Pennelli et al. [51] 
got near results and concluded that Galectin-3 
cytotest was less informative in follicular carcinoma 
than in papillary carcinoma. Saggiorato et al. [14] 
applied the Galectin-3 on the cytological samples and 
their post-operative specimen and noticed that the 
negative follicular carcinoma cases by 
immunocytochemisty were related to minimally 
invasive tumors. Batolazzi et al. [15] have 
hypothesized that these false negative cases may be 
due to technical failure or probably because of 
additional molecular alterations that affect LGALS3 
gene transcription, and they suggested the possibility 
of further study. Herrman et al. [57] supposed that a 
sampling error occurred in the FNAB technique, or 
that a technical error occurred in the fixation 
procedure. Considering that galectin-3 may show 
focal expression, Bartolazzi et al. [15]
 
hypothesized 
that FNA  sampled areas where those  that did not 
express the molecule, and they suggested the use of 
large needle aspiration cytology to ensure better 
material sufficient for cell block preparation and  fair  
immunostaining  evaluation. 
In the benign group, Galectin-3 showed 
moderate positivity in a case of MNG and a case of 
follicular adenoma, two cases of follicular adenoma 
showed focal positivity, while the rest of cases in both 
categories were negative for Galectin-3. We found 
that the three positive cases of follicular adenoma 
were histologically of microfollicular variant. Saleh et 
al. [58] explained the presence of some positive MNG 
cases were due to macrophages positively staining 
with Galectin - 3, and this may obscure the follicular 
cells mainly in the presence of cystification. Therefore, 
positivity of follicular cells in these cases may be false 
due to carry-over of the associated abundant 
macrophages. They studied Galectin-3 on histological 
sections and also observed that the MNG positivity in 
some case were related to cystified or inflamed areas 
and hypothesized that  expression of non-neoplastic 
follicular cells in inflamed areas may result from 
cytokines secreted by the inflammatory cells or simple 
permeation of galectin-3 abundantly shed by 
lymphocytes in the neighboring follicular cells. 
Therefore, they suggested that Galectin-3 results 
have to be evaluated in conjunction with other 
features. 
Martins et al. [59] applied Galectin-3 on 
histological sections and noticed that in false positive 
cases of follicular adenomas the expression of 
galectin-3 is restricted to follicular cells
 
bordering the 
connective capsule, suggesting it might be related
 
to 
malignant transformation and malignant progression. 
The same suggestion was made by Aiad et al. [53], 
when they applied Galectin-3 to both cytological 
preparations and their post operative histological 
sections. None of these studies commented on the 
adenoma variant in positive cases. 
The presence of false positive cases was also 
noticed by Collet et al. [60], they suggested that these 
benign lesions (MNG and adenomas) present foci of 
clonal expansion, suggesting a stage in the multistep 
evolution
 
of goiters and adenomas to carcinoma, and 
they concluded that, adenomas with positive 
expression for galectin-3
 
could be considered potential 
early cancer, and hence require therapeutic
 
surgical 
intervention.. The same recommendations were also 
made by Saggirato et al. [14] and Bartolazzi et al. [15] 
and Lubiz et al. [29] they also suggested that a new 
possibility of early detection of thyroid cancer can be 
accomplished by Galectin-3 immunostaining method, 
and they recommended further work to ensure the 
accuracy of this suggestion.       
In all studied cases, the  ancillary techniques 
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used in the study (Galectin-3 and DNA ploidy) could 
refine the FNA results and  increase its sensitivity as a 
screening test from sensitivity (60%) to reach 
sensitivity (93.3%) and (90%) respectively, thus 
decreasing the false negative cases.  
However, in the present work, we had 25 
cases which were placed in the indeterminate grey 
zone of “follicular neoplasm” by the conventional 
cytological evaluation. Focusing on these cases,   
Galectin-3 could screen malignancy with sensitivity of 
83.3%, specificity 84.6%, and 84% diagnostic 
accuracy. DNA ploidy could predict malignancy within 
this group with sensitivity 83.3%, specificity 76.9%, 
and 80% diagnostic accuracy.  
The utility of Galectin-3 in indeterminate 
thyroid cytology was supported by Saggiorato et al. 
[14], and Bartolazzi et al. [15], they suggest the use of 
galectin-3 in the selected indeterminate cases by 
conventional cytology aiming to decrease the number 
of unnecessary surgeries. The role of DNA ploidy 
assessment in the risky cases of follicular neoplasms 
was highlighted by Wang et al. [61] and Ismail et al. 
[62], all considered DNA ploidy a helpful tool in solving 
the diagnostic dilemma of the “follicular neoplasm”.  
However, other studies as Aron et al. [63] and 
Nguyen et al. [64] denied any role for galectin-3 or 
DNA ploidy assessment respectively in solving these 
problematic cases and they suggested that all thyroid 
follicular neoplasia are best excised for proper 
histopathological examination, as the histologic 
determination of capsular and / or vascular invasion is 
the only way to differentiate benign and malignant 
cases within this group. To date, no method on its 
own appeared to be perfect, and the, DNA ploidy and 
immunocytochemical markers would in combination, 
help in solving the diagnostic dilemma of the 
indeterminate cytology. 
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